Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness-Reference-Cited by-同舟云学术

Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

Published:2010-12-21 Issue:12 Volume:4 Page:e923
ISSN:1935-2735
Container-title:PLoS Neglected Tropical Diseases
language:en
Short-container-title:PLoS Negl Trop Dis

Author:

Torreele Els,Bourdin Trunz Bernadette,Tweats David,Kaiser Marcel,Brun Reto,Mazué Guy,Bray Michael A.,Pécoul Bernard

Publisher

Public Library of Science (PLoS)

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference62 articles.

1. The impact of diversity-based, high-throughput screening on drug discovery: “chance favours the prepared mind”.;M Snowden;Curr Opin Drug Discov Devel,2008

2. HTS and hit finding in academia–from chemical genomics to drug discovery. Drug Discov Today 14: 1150-1158.;JA Frearson;Epub 2009 Sep,2009

3. Protein kinase inhibitors: insights into drug design from structure.;ME Noble;Science,2004

4. WHO fact sheet.

5. Human African trypanosomiasis (sleeping sickness): epidemiological update.;WHO;Weekly Epidemiological Record,2006

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and Synthesis of Novel 3-Nitro-1H-1,2,4-triazole-1,2,3-triazole-1,4-disubstituted Analogs as Promising Antitrypanosomatid Agents: Evaluation of In Vitro Activity against Chagas Disease and Leishmaniasis;Journal of Medicinal Chemistry;2024-02-02

2. Antigiardial and antiamebic activities of fexinidazole and its metabolites: new drug leads for giardiasis and amebiasis;Antimicrobial Agents and Chemotherapy;2024-01-10

3. Discovery of an orally active nitrothiophene-based antitrypanosomal agent;European Journal of Medicinal Chemistry;2024-01

4. Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial;The Lancet Infectious Diseases;2024-01

5. Clinical trials for Chagas disease: etiological and pathophysiological treatment;Frontiers in Microbiology;2023-12-15